• In late June 2026, Oruka Therapeutics, Inc. (NasdaqGM: ORKA) was removed from several Russell value and microcap indices and simultaneously added to multiple Russell growth benchmarks, including the Russell 2000 and 3000 Growth indices.
• This reshuffling signals a formal shift in how index providers classify Oruka’s profile, potentially altering which passive funds and style-focused investors hold the stock.
• We’ll now examine how Oruka’s reclassification from value and microcap indices into Russell growth benchmarks shapes the company’s evolving investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.

What Is Oruka Therapeutics' Investment Narrative?

To own Oruka Therapeutics today, you effectively have to believe in its early clinical story around long-acting IL-23 and IL-17 antibodies, despite zero revenue and sizeable ongoing losses. The key near term catalysts are clearly clinical: fuller EVERLAST-A psoriasis data in the second half of 2026 and the launch and readout of Phase 2 programs for ORKA-001 and ORKA-002, alongside any partnering activity around these assets. The recent shift from Russell value and microcap indices into Russell growth benchmarks mostly reinforces how the market is already treating Oruka, as a higher risk, higher expectation growth biotech rather than a beaten-down value name. That reclassification could influence which funds trade the stock, but it does not change the core risks around funding requirements, trial execution and a rich valuation on a price to book basis. Yet the possibility of further dilution and funding pressure is something investors should watch closely.

Our comprehensive valuation report raises the possibility that Oruka Therapeutics is priced higher than what may be justified by its financials.

Exploring Other Perspectives

The Simply Wall St Community’s two fair value estimates for Oruka span a wide range, from about US$14 to roughly US$142 per share, underscoring how far apart views on upside are. When you set that against an early stage pipeline, continued losses and the recent shift into growth indices, it is clear that different investors can be anchoring on very different risk and reward assumptions, so it is worth exploring several of these perspectives before forming your own view.

Explore 2 other fair value estimates on Oruka Therapeutics - why the stock might be worth less than half the current price!

Decide For Yourself

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Oruka Therapeutics research is our analysis highlighting 4 important warning signs that could impact your investment decision.
• Our free Oruka Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Oruka Therapeutics' overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.